Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05974904 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 28, 2024 to Dec 28, 2026v4
  2. Primary and study completion dates: Dec 28, 2023 to Dec 28, 2024v3
  3. Primary and study completion dates: Jul 28, 2023 to Dec 28, 2023
    • Study title expanded, about 2 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD). The main question\[s\] it aims to answer are: \[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Trial Details
NCT Number NCT05974904
Lead Sponsor Chongqing Medical University
Conditions
(from sponsor)		 Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
Related terms Fatty Liver, Inflammation, Liver Cirrhosis
Enrollment 7,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov